Wegovy, also known as semaglutide, is an FDA-approved medication designed to aid in weight loss for individuals struggling with obesity.
Wegovy works by mimicking the hormone GLP-1, which regulates appetite and food intake, leading to reduced calorie consumption and weight loss.
Clinical trials have demonstrated remarkable results, with participants experiencing significant weight loss over extended periods.
In addition to aiding weight loss, Wegovy has shown potential benefits in improving metabolic health, reducing the risk of cardiovascular diseases, and enhancing overall well-being.
Wegovy is administered via a once-weekly injection, making it convenient for long-term adherence and effectiveness.
It is recommended for adults with a BMI of 30 or higher, or those with a BMI of 27 or higher with weight-related health conditions.
Common side effects include nausea, diarrhea, and constipation, typically resolving with continued use.
Wegovy is most effective when combined with a balanced diet and regular physical activity, supporting sustainable weight loss and fitness goals.